2022 World Conference on Lung Cancer (ePosters)-EP08.03-001. A Clinical Study on the Safety and Efficacy of Aumolertinib Combined with SBRT in the EGFR-mutant NSCLC with Brain Parenchymal Oligometastases

EP08.03-001. A Clinical Study on the Safety and Efficacy of Aumolertinib Combined with SBRT in the EGFR-mutant NSCLC with Brain Parenchymal Oligometastases

Back to course

Pdf Summary

This clinical study aimed to evaluate the safety and efficacy of combining Aumolertinib with stereotactic body radiation therapy (SBRT) in patients with EGFR-mutant NSCLC and brain oligometastases. Brain metastasis in NSCLC patients with EGFR mutations is a common treatment failure pattern. Brain oligometastasis, defined as having less than 5 metastatic tumors, is considered potentially curable. SBRT can increase the permeability of the blood-brain barrier, resulting in higher concentrations of Aumolertinib in the brain.<br /><br />The study included patients aged 18-80 with confirmed EGFR-sensitive mutations in stage IV pulmonary adenocarcinoma. Patients with severe systemic infections or other serious diseases were excluded. The primary objective was to assess the efficacy of Aumolertinib with SBRT based on objective response rate (ORR) according to RECIST v1.1. Secondary objectives included assessing progression-free survival (PFS), overall survival (OS), and intracranial ORR, disease control rate (DCR), and PFS.<br /><br />Ten patients have been recruited so far. The ORR was 90%, indicating a high response rate to the Aumolertinib SBRT combination. The median PFS was 245 days, and the median intracranial PFS was 262 days. The overall survival has not yet been reached.<br /><br />This study suggests that combining Aumolertinib with SBRT may be a safe and effective therapeutic option for NSCLC patients with EGFR-mutant and brain oligometastasis. The high response rate and promising PFS outcomes indicate the potential for improved treatment outcomes in this patient population. Further investigation and larger trials are needed to confirm these findings and determine long-term survival benefits.

Asset Subtitle

Chunyu He

Meta Tag

Speaker Chunyu He

Topic Metastatic Non-small Cell Lung Cancer Oligometastatic Disease

Keywords

clinical study

Aumolertinib

SBRT

EGFR-mutant NSCLC

brain oligometastases

blood-brain barrier

objective response rate

progression-free survival

overall survival

high response rate